Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

10-day vs 5-day decitabine: equivalence cannot be concluded.

Huls G, Suciu S, Wijermans P, Kicinski M, Lübbert M.

Lancet Haematol. 2019 Apr;6(4):e177. doi: 10.1016/S2352-3026(19)30024-9. No abstract available.

PMID:
30926076
2.

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.

Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M.

Haematologica. 2019 Jan;104(1):59-69. doi: 10.3324/haematol.2017.187278. Epub 2018 Aug 31.

3.

Hereditary elliptocytosis: Variable clinical severity caused by 3 variants in the α-spectrin gene.

Franck P, Postma C, Spaans A, Veuger M, de Kort G, Hudig C, Wijermans P, Kuypers F.

Int J Lab Hematol. 2018 Aug;40(4):e66-e70. doi: 10.1111/ijlh.12837. Epub 2018 May 5. No abstract available.

PMID:
29729090
4.

Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Persoon S, ChinAPaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ.

PLoS One. 2017 Jul 20;12(7):e0181313. doi: 10.1371/journal.pone.0181313. eCollection 2017.

5.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
6.

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).

Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E, Claus R.

Br J Haematol. 2017 Feb;176(4):609-617. doi: 10.1111/bjh.14463. Epub 2016 Dec 1.

PMID:
27905102
7.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

8.

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P.

Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11. No abstract available.

9.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

10.

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.

11.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

12.

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study.

van der Poel MW, Mulder WJ, Ossenkoppele GJ, Maartense E, Hoogendoorn M, Wijermans P, Schouten HC.

Ann Hematol. 2015 Aug;94(8):1373-9. doi: 10.1007/s00277-015-2358-3. Epub 2015 Apr 14.

13.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.

Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.

14.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
15.

Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists.

van der Poel MW, Mulder WJ, Ossenkoppele GJ, Maartense E, Wijermans P, Hoogendoorn M, Schouten HC.

Neth J Med. 2014 Apr;72(3):165-9.

16.

Clinical Results of Hypomethylating Agents in AML Treatment.

Cruijsen M, Lübbert M, Wijermans P, Huls G.

J Clin Med. 2014 Dec 25;4(1):1-17. doi: 10.3390/jcm4010001. Review.

17.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

18.

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA.

Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8.

PMID:
24268350
19.

The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.

Evers D, Kerkhoffs JL, Van Egmond L, Schipperus MR, Wijermans PW.

J Clin Apher. 2014 Jun;29(3):133-8. doi: 10.1002/jca.21303. Epub 2013 Oct 15.

PMID:
24130064
20.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
21.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

22.

The efficiency of therapeutic erythrocytapheresis compared to phlebotomy in relation to blood volume and delta-hematocrit: an evaluation in hereditary hemochromatosis polycythemia vera and secondary erythrocytosis.

Evers D, Kerkhoffs JL, Van Egmond L, Wijermans PW.

Transfus Apher Sci. 2013 Apr;48(2):187. doi: 10.1016/j.transci.2013.02.030. Epub 2013 Mar 13. No abstract available.

PMID:
23809828
23.

A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands.

Klodzinska S, Vos JM, Kersten MJ, Wijermans P, Minnema MC.

Neth J Med. 2013 Mar;71(2):90-6.

24.

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party.

Neth J Med. 2013 Mar;71(2):54-62.

25.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A.

Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.

26.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK.

Br J Haematol. 2013 May;161(3):357-66. doi: 10.1111/bjh.12266. Epub 2013 Feb 25.

27.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B.

Blood. 2012 Dec 6;120(24):4706-11. doi: 10.1182/blood-2012-04-420596. Epub 2012 Oct 9.

28.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P.

Haematologica. 2013 Jan;98(1):87-94. doi: 10.3324/haematol.2012.067058. Epub 2012 Aug 8.

29.

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.

Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M, Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lübbert M.

Haematologica. 2013 Feb;98(2):208-16. doi: 10.3324/haematol.2012.067892. Epub 2012 Aug 8.

30.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.

J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

PMID:
22802322
31.

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B.

J Clin Oncol. 2012 Jun 10;30(17):2140-6. doi: 10.1200/JCO.2011.39.6499. Epub 2012 May 7.

PMID:
22564995
32.

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.

Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1457-66. doi: 10.1007/s00280-012-1850-x. Epub 2012 Mar 1.

PMID:
22382880
33.

Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.

Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ; HOVON; Dutch-Belgian Cooperative Group for Hematological Oncology.

Leukemia. 2012 Jul;26(7):1726-9. doi: 10.1038/leu.2012.53. Epub 2012 Feb 23. No abstract available.

PMID:
22358264
34.

[Demethylating medication in myelodysplastic syndrome].

Manson ML, Derissen EJ, Wijermans PW, Schellens JH, Beijnen JH.

Ned Tijdschr Geneeskd. 2012;156(4):A3167. Review. Dutch.

PMID:
22278034
35.

IMWG consensus on maintenance therapy in multiple myeloma.

Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M; International Myeloma Working Group.

Blood. 2012 Mar 29;119(13):3003-15. doi: 10.1182/blood-2011-11-374249. Epub 2012 Jan 23. Review.

36.

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H.

Haematologica. 2012 Mar;97(3):393-401. doi: 10.3324/haematol.2011.048231. Epub 2011 Nov 4.

37.

Feasibility of nonselective testing for hemoglobinopathies in early pregnancy in The Netherlands.

Kaufmann JO, Demirel-Güngör G, Selles A, Hudig C, Steen G, Ponjee G, Holleboom C, Freeman LM, Hendiks J, Wijermans P, Giordano PC, Kerkhoffs JL.

Prenat Diagn. 2011 Dec;31(13):1259-63. doi: 10.1002/pd.2882. Epub 2011 Oct 26.

PMID:
22031467
38.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
39.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network.

Blood. 2011 Aug 4;118(5):1239-47. doi: 10.1182/blood-2011-03-341669. Epub 2011 Jun 13.

40.

Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

Rijneveld AW, van der Holt B, Daenen SM, Biemond BJ, de Weerdt O, Muus P, Maertens J, Mattijssen V, Demuynck H, Legdeur MC, Wijermans PW, Wittebol S, Spoelstra FM, Dekker AW, Ossenkoppele GJ, Willemze R, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group.

Leukemia. 2011 Nov;25(11):1697-703. doi: 10.1038/leu.2011.141. Epub 2011 Jun 7.

PMID:
21647160
41.

Regression of HIV-associated grade IV T cell lymphoma with combined antiretroviral therapy only.

Teng YKO, Schippers EF, Wijermans PW.

Int J Hematol. 2011 Jun;93(6):811-814. doi: 10.1007/s12185-011-0859-y. Epub 2011 May 11. Review.

PMID:
21557043
42.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
43.

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.

Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON).

Ann Hematol. 2011 Dec;90(12):1427-39. doi: 10.1007/s00277-011-1224-1. Epub 2011 Apr 7.

PMID:
21472373
44.

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).

Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, Ferrant A, Biron P, Crawley C, Schattenberg A, Luan JJ, Tilly H, Rio B, Wijermans PW, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ann Oncol. 2012 Jan;23(1):166-71. doi: 10.1093/annonc/mdr035. Epub 2011 Apr 5.

PMID:
21467125
45.

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.

Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A.

Blood. 2011 Mar 17;117(11):3025-31. doi: 10.1182/blood-2010-09-307645. Epub 2011 Jan 12.

46.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON.

J Clin Oncol. 2010 Jul 1;28(19):3160-6. doi: 10.1200/JCO.2009.26.1610. Epub 2010 Jun 1.

PMID:
20516439
47.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R.

Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21.

48.

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.

Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):138-43. doi: 10.3816/CLML.2010.n.020.

PMID:
20371448
49.

Hb Den Haag [beta45(CD4)Phe-->Tyr]. A new hemoglobin variant observed during early pregnancy diagnostics.

Kaufmann JO, Harteveld CL, Bakker-Verweij M, Arkesteijn SG, van Delft P, Haak H, Wijermans PW, Kerkhoffs JL, Giordano PC.

Hemoglobin. 2010;34(1):37-44. doi: 10.3109/03630260903547435.

PMID:
20113286
50.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Haematologica. 2010 Jun;95(6):914-21. doi: 10.3324/haematol.2009.016766. Epub 2009 Dec 16.

Supplemental Content

Loading ...
Support Center